Amivantamab Intravenous
Phase 3
Johnson & JohnsonAmivantamab Intravenous is one of 13 therapeutic programs targeting Advanced or Metastatic Non-small Cell Lung Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in Advanced or Metastatic Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Lazcluze
Johnson & JohnsonPhase 3
Rybrevant
Johnson & JohnsonPhase 3
Ceralasertib
AstraZenecaPhase 3
Amivantamab Intravenous
Johnson & JohnsonPhase 3
Taxol
TevaPreclinical
Abraxane
Bristol-Myers SquibbPreclinical
Cyramza
Eli LillyPreclinical
Alimta
SShawn Eagle
Preclinical
Alimta
EEagle Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced or Metastatic Non-small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Amivantamab Intravenous. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company